image
Healthcare - Biotechnology - NASDAQ - US
$ 0.8009
0.894 %
$ 67.6 M
Market Cap
-0.27
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STRO stock under the worst case scenario is HIDDEN Compared to the current market price of 0.801 USD, Sutro Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STRO stock under the base case scenario is HIDDEN Compared to the current market price of 0.801 USD, Sutro Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one STRO stock under the best case scenario is HIDDEN Compared to the current market price of 0.801 USD, Sutro Biopharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STRO

image
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.4Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
62 M REVENUE
-59.64%
-238 M OPERATING INCOME
-167.09%
-227 M NET INCOME
-112.99%
-192 M OPERATING CASH FLOW
-71.61%
219 M INVESTING CASH FLOW
5668.50%
94.1 M FINANCING CASH FLOW
-31.62%
17.4 M REVENUE
17.49%
-68.5 M OPERATING INCOME
-4.99%
-76 M NET INCOME
-4.87%
-67.9 M OPERATING CASH FLOW
5.37%
-16.3 M INVESTING CASH FLOW
-18.58%
66 K FINANCING CASH FLOW
375.00%
Balance Sheet Sutro Biopharma, Inc.
image
Current Assets 343 M
Cash & Short-Term Investments 317 M
Receivables 8.62 M
Other Current Assets 17.8 M
Non-Current Assets 43.9 M
Long-Term Investments 0
PP&E 35.9 M
Other Non-Current Assets 8.03 M
81.84 %4.60 %9.26 %Total Assets$387.2m
Current Liabilities 132 M
Accounts Payable 10.5 M
Short-Term Debt 7.48 M
Other Current Liabilities 114 M
Non-Current Liabilities 211 M
Long-Term Debt 15.7 M
Other Non-Current Liabilities 195 M
3.06 %33.26 %4.57 %56.93 %Total Liabilities$342.6m
EFFICIENCY
Earnings Waterfall Sutro Biopharma, Inc.
image
Revenue 62 M
Cost Of Revenue 0
Gross Profit 54.8 M
Operating Expenses 300 M
Operating Income -238 M
Other Expenses -11 M
Net Income -227 M
100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)62m055m(300m)(238m)11m(227m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
88.37% GROSS MARGIN
88.37%
-384.34% OPERATING MARGIN
-384.34%
-366.62% NET MARGIN
-366.62%
-509.99% ROE
-509.99%
-58.74% ROA
-58.74%
-91.69% ROIC
-91.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sutro Biopharma, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -227 M
Depreciation & Amortization 7.22 M
Capital Expenditures -3.1 M
Stock-Based Compensation 24.7 M
Change in Working Capital 8.9 M
Others -24.2 M
Free Cash Flow -195 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sutro Biopharma, Inc.
image
Wall Street analysts predict an average 1-year price target for STRO of $10.2 , with forecasts ranging from a low of $2 to a high of $15 .
STRO Lowest Price Target Wall Street Target
2 USD 149.72%
STRO Average Price Target Wall Street Target
10.2 USD 1179.81%
STRO Highest Price Target Wall Street Target
15 USD 1772.89%
Price
Max Price Target
Min Price Target
Average Price Target
16161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Sutro Biopharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. zacks.com - 1 month ago
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - globenewswire.com - 1 month ago
Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. globenewswire.com - 2 months ago
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - globenewswire.com - 2 months ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - globenewswire.com - 3 months ago
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline. benzinga.com - 3 months ago
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago. zacks.com - 3 months ago
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – globenewswire.com - 3 months ago
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline – Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – globenewswire.com - 3 months ago
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA. globenewswire.com - 4 months ago
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA. globenewswire.com - 5 months ago
8. Profile Summary

Sutro Biopharma, Inc. STRO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 67.6 M
Dividend Yield 0.00%
Description Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Contact 111 Oyster Point Boulevard, South San Francisco, CA, 94080 https://www.sutrobio.com
IPO Date Sept. 27, 2018
Employees 269
Officers Dr. Barbara Leyman Ph.D. Chief Business Officer Ms. Regina Cheng Vice President & Controller Dr. Hans-Peter Gerber Ph.D. Chief Scientific Officer Ms. Jane Chung R.Ph. Chief Executive Officer & Director Mr. Edward C. Albini M.B.A Chief Financial Officer & Secretary Dr. Venkatesh Srinivasan Ph.d. Chief Technical Operations Officer Dr. James R. Swartz DSc, Ph.D., Sc.D. Founder Mr. David Pauling J.D., M.A. Chief Administrative Officer & General Counsel